QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Screening using PSA has a high false-positive rate. Genome-wide association studies have identified common germline genetic variants that can be used to calculate a polygenic risk score (PRS) associated with prostate cancer risk. To test the usefulness of a PRS…
Limitations for Informing Current Patient Management The UK’s “ProtecT” randomized clinical trial compares treatment outcomes from 2,640 men with PSA-based, screen-detected localized prostate cancer randomized to treatment with either “active monitoring, ” radical prostatectomy, or radiotherapy. In 2020, the trial…
This study examined different treatments for localized prostate cancer and their effect on long-term survival. Localized prostate cancer means the cancer has not spread beyond the prostate. There is still debate overwhich treatment is most effective. The researchers used data…
This study focused on comparing two imaging methods—18F-PSMA-1007 PET/CT and multiparametric MRI—to see which one is more accurate at detecting the extent of prostate cancer before surgery in men with intermediate- or high-risk disease. Prostate-specific membrane antigen (PSMA) is a…
This study examined how well a type of medical scan called PSMA-PET can predict survival outcomes in men with prostate cancer. PSMA-PET has become an essential tool for diagnosing and staging prostate cancer since it was introduced in 2012….
Dear patients, friends, research participants, colleagues and other loyal supporters: As the end of the year approaches, let me take this opportunity to express my profound gratitude to the many people without whose collaboration and support the successes of…
The news that former President Joe Biden has been diagnosed with a highly aggressive form of prostate cancer presents an opportunity to examine critical information that could help thousands of men avoid this life-threatening situation. Biden was diagnosed after he…
Screening for prostate cancer is controversial, but it shouldn’t be. In the U.S., prostate cancer is the most common non-skin cancer and the second-leading cause of cancer death in men, with an estimated 313,780 new cases being diagnosed in 2025,…
Because PSA screening has false positives, enhancements have been sought to increase the specificity of PSA testing. PSA Velocity (PSAV) correlates with both prostate cancer risk and aggressiveness. PSAV Risk Count quantifies the persistence of PSA increases over time,…
There are now many current treatment options for men with LUTS (lower urinary tract symptoms) from BPH (benign prostatichyperplasia). The first and simplest step is oral alpha-blocker medications. Alpha-blockers work by relaxing the musclesin the prostate and the bladder…
"*" indicates required fields
